Companies › Jiangsu Renocell Biotech Company
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Immunology; next expected readout Dec 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| RY_SW01 cell injection Umbilical cord-derived mesenchymal stem cells (UC-MSCs) with immunomodulatory and tissue-r | – | Phase 2 | Lupus Nephritis; Systemic Sclerosis | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06058078 | RY_SW01 cell injection | Phase 2 | Lupus Nephritis | Immunology | Dec 2028 |
| NCT06058091 | RY_SW01 cell injection | Phase 1 | Systemic Sclerosis | Immunology | Dec 2035 |
No annotated target.
–
Cynata Therapeutics Wuxi Cellular Biopharmaceutical Group Artiva Biotherapeutics Kyverna Therapeutics Apogee Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.